EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer

The combination of masofaniten and enzalutamide for treatment-naïve mHSPC did show efficacy and had an acceptable safety profile. These results support further investigation of the dual AR blockade in mHSPC (ClinicalTrials.gov Identifier: NCT06312670).

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2025-12-30
DOI
https://doi.org/10.1093/oncolo/oyaf434
Citations
1
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer

Karen Villaluna, Abby Grier, Albert Jang, J GARCIA et al.
1 citations
The Oncologist
Prostate Cancer Treatment and Research
1.52
article

EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer

Karen Villaluna, Abby Grier, Albert Jang, J GARCIA, Seunghee Margevicius, Christopher Eing Wee, Jeffrey Zhong, P. Fu, Pedro Coelho Barata, Tanya Jindal, Jason Robert Brown, Brett S. Younginger, Prateek Mendiratta, Rishi Patel, Mary Hislop, Amy L. Reese, Iris Yeong- Fung Sheng, Kathryn Helminiak, Hannah Garcia, Shilpa Gupta, Amanda Nizam, Julie Bray, Hamsa L S Kumar, Timothy Adamowicz, Jeffrey Pasucal, Kayla Wolff, Kara Richey, Victoria Delong, Peggy Fowler, Alessandra Cesano
article en
1 citations

Abstract

The combination of masofaniten and enzalutamide for treatment-naïve mHSPC did show efficacy and had an acceptable safety profile. These results support further investigation of the dual AR blockade in mHSPC (ClinicalTrials.gov Identifier: NCT06312670).

The OncologistVol. 31(2)
National Academy of Governance (MN), Cleveland Clinic (US), University Hospitals of Cleveland (US), Firelands Regional Medical Center (US), Essa Pharma (United States) (US), University Hospitals Cleveland Medical Center (US), University Hospitals Seidman Cancer Center (US), Case Western Reserve University (US)
Openalex Percentile: Top 12%
Prostate Cancer Treatment and Research
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.